Payment overview · 2025
General Payments
$1,810.17
77 reported records · 16 companies
Healthcare provider profile · identity verified
Noli A. Cava, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1265453435
Verified facts
What the public records show
CMS Open Payments records show Noli A. Cava, M.D. received $1,810.17 in general payments during 2025 across 77 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $718.68 | 39.7% | 27 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $226.52 | 12.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $196.05 | 10.8% | 12 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $135.22 | 7.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.02 | 6.8% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $88.44 | 4.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.40 | 3.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $56.94 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.88 | 2.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $35.78 | 2.0% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.75 | 1.8% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $26.74 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.60 | 1.1% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.59 | 0.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.50 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,810.17 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $569.46 | 20 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $245.58 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $202.88 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $135.22 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $130.76 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.76 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $88.44 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.65 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $59.37 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $56.94 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $46.88 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $44.26 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $35.78 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $31.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 188 |
| Losartan Potassium | Losartan Potassium | 456 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 122 |
| Metformin Hcl | Metformin Hcl | 356 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 294 | 63 |
| Alprazolam | Alprazolam | 262 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 262 | 36 |
| Lisinopril | Lisinopril | 255 | 74 |
| Gabapentin | Gabapentin | 251 | 58 |
| Simvastatin | Simvastatin | 215 | 58 |
| Tramadol Hcl | Tramadol Hcl | 210 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 169 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 42 |
| Omeprazole | Omeprazole | 156 | 50 |
| Furosemide | Furosemide | 147 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 41 |
| Trazodone Hcl | Trazodone Hcl | 125 | 41 |
| Famotidine | Famotidine | 120 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 36 |
| Temazepam | Temazepam | 99 | 15 |
| Lorazepam | Lorazepam | 97 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 23 |
| Carvedilol | Carvedilol | 87 | 28 |
| Alendronate Sodium | Alendronate Sodium | 84 | 26 |
| Allopurinol | Allopurinol | 83 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 26 |
| Sertraline Hcl | Sertraline Hcl | 82 | 27 |
| Clonazepam | Clonazepam | 80 | 11 |
| Potassium Chloride | Potassium Chloride | 79 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 30 |
| Trulicity | Dulaglutide | 77 | 12 |
| Glimepiride | Glimepiride | 76 | 19 |
| Montelukast Sodium | Montelukast Sodium | 75 | 27 |
| Finasteride | Finasteride | 72 | 22 |
| Eliquis | Apixaban | 71 | 26 |
| Farxiga | Dapagliflozin Propanediol | 69 | 17 |
| Ibuprofen | Ibuprofen | 68 | 28 |
| Meclizine Hcl | Meclizine Hcl | 66 | 22 |
| Baclofen | Baclofen | 60 | 18 |
| Nifedipine Er | Nifedipine | 60 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Diazepam | Diazepam | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 11 |
| Ozempic | Semaglutide | 53 | 16 |
| Atenolol | Atenolol | 52 | 14 |
| Celecoxib | Celecoxib | 52 | 15 |
| Lovastatin | Lovastatin | 51 | 12 |
| Prednisone | Prednisone | 51 | 11 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Carisoprodol | Carisoprodol | 50 | suppressed |
| Xarelto | Rivaroxaban | 48 | 11 |
| Meloxicam | Meloxicam | 46 | 19 |
| Azithromycin | Azithromycin | 45 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 16 |
| Glipizide | Glipizide | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 15 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 28 |
| Pregabalin | Pregabalin | 38 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | 15 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 12 |
| Jardiance | Empagliflozin | 35 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,810.17 · 77 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, AREXVY, AUSTEDO XR, BREZTRI, CeQur Simplicity, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, KISUNLA, LOREEV XR, MOUNJARO, NURTEC ODT, SHINGRIX, TEPEZZA, TRELEGY ELLIPTA, Tlando, UBRELVY, VYNDAQEL, ZAVZPRET, ZEPBOUND, ZORYVE, bio-ConneKt | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error